ArticleAnnals of medicine2026
Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentifying chronic hepatitis B (CHB) patients likely to achieve hepatitis B surface antigen (HBsAg) sero-clearance upon receiving pegylated interferon α (PEG-IFNα) could aid in optimizing treatment strategies for "functional cure".
aimsTo develop a group-based trajectory model (GBTM) for identifying PEG-IFNα-treated CHB patients likely to achieve HBsAg sero-clearance.
methodsBaseline characteristics were obtained from 342 PEG-IFNα-treated CHB patients, divided into training (205), validation (88), and testing (49) datasets
results131 patients (38.30%) were functionally cured, and GBTM identified 3 trajectory groups, associated with rapid (traj_1), moderate (traj_2), and slow (traj_3) HBsAg declines. Traj_3 had the highest viral burden, plus lowered liver functions. The GBTM-based 3-group trajectory model was highly accurate under ROC, with areas under the curve >0.920, while calibration curves had high predicted-actual outcome correspondence, for all 3 datasets. Clinical utility was also high under DCA, and the website correctly found the trajectory group of a CHB patient, based on HBsAg from ≥2 different time points.
conclusionsThe GBTM-based 3-group trajectory model correctly identified PEG-IFNα-treated CHB patients likely to be "functionally cured", thereby providing a tool for devising personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.